Scarica l'app Stockscreener
294.06
2.04%
5.88
Dopo l'orario di chiusura:
293.00
-1.06
-0.36%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ALNY Giù?
Forum
Previsione
Precedente Chiudi:
$288.18
Aprire:
$290.95
Volume 24 ore:
1.30M
Relative Volume:
1.14
Capitalizzazione di mercato:
$39.26B
Reddito:
$4.29B
Utile/perdita netta:
$577.22M
Rapporto P/E:
69.87
EPS:
4.2086
Flusso di cassa netto:
$641.34M
1 W Prestazione:
+4.01%
1M Prestazione:
-1.14%
6M Prestazione:
-26.61%
1 anno Prestazione:
-9.52%
Intervallo 1D:
$288.85
$303.46
Intervallo di 1 settimana:
$273.11
$303.46
Portata 52W:
$273.11
$495.55
Alnylam Pharmaceuticals Inc Stock (ALNY) Company Profile
Nome
Alnylam Pharmaceuticals Inc
Settore
Industria
Telefono
(617) 551-8200
Indirizzo
675 WEST KENDALL STREET, CAMBRIDGE, MA
Compare ALNY vs VRTX, REGN, ARGX, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ALNY
Alnylam Pharmaceuticals Inc
|
294.06 | 38.48B | 4.29B | 577.22M | 641.34M | 4.2086 |
VRTX
Vertex Pharmaceuticals Inc
|
475.20 | 118.89B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
623.43 | 64.79B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
852.50 | 53.07B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
169.77 | 36.04B | 742.00K | -1.37B | -1.07B | -7.0731 |
Alnylam Pharmaceuticals Inc Stock (ALNY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-16 | Downgrade | Jefferies | Buy → Hold |
| 2026-01-28 | Ripresa | Barclays | Overweight |
| 2026-01-07 | Ripresa | Oppenheimer | Outperform |
| 2025-08-04 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2025-08-04 | Aggiornamento | Wolfe Research | Underperform → Peer Perform |
| 2025-07-30 | Ripresa | Raymond James | Outperform |
| 2025-07-21 | Iniziato | Truist | Buy |
| 2025-03-31 | Iniziato | Redburn Atlantic | Buy |
| 2025-03-24 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2024-11-12 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| 2024-10-16 | Iniziato | Scotiabank | Sector Outperform |
| 2024-08-16 | Aggiornamento | Goldman | Neutral → Buy |
| 2024-02-16 | Downgrade | Goldman | Buy → Neutral |
| 2024-02-15 | Iniziato | Wolfe Research | Peer Perform |
| 2023-12-08 | Iniziato | Wells Fargo | Equal Weight |
| 2023-10-11 | Downgrade | Oppenheimer | Outperform → Perform |
| 2023-09-29 | Iniziato | Raymond James | Outperform |
| 2023-05-05 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-26 | Iniziato | SMBC Nikko | Neutral |
| 2023-03-21 | Iniziato | Bernstein | Outperform |
| 2023-01-18 | Iniziato | Canaccord Genuity | Buy |
| 2022-09-09 | Ripresa | Morgan Stanley | Equal-Weight |
| 2022-07-13 | Iniziato | Cantor Fitzgerald | Neutral |
| 2022-06-27 | Downgrade | Guggenheim | Buy → Neutral |
| 2022-06-07 | Iniziato | William Blair | Outperform |
| 2022-04-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2022-03-01 | Iniziato | Citigroup | Buy |
| 2022-02-03 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2022-01-03 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2021-11-22 | Aggiornamento | Goldman | Neutral → Buy |
| 2021-11-22 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-11-01 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2021-10-04 | Aggiornamento | UBS | Neutral → Buy |
| 2021-08-04 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-02-22 | Downgrade | Guggenheim | Buy → Neutral |
| 2021-02-12 | Downgrade | Citigroup | Buy → Neutral |
| 2021-02-12 | Reiterato | H.C. Wainwright | Buy |
| 2021-01-25 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-30 | Ripresa | Berenberg | Hold |
| 2020-09-08 | Iniziato | Citigroup | Buy |
| 2020-08-11 | Downgrade | Oppenheimer | Outperform → Perform |
| 2020-05-13 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2020-05-07 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-04-24 | Ripresa | Evercore ISI | Outperform |
| 2020-03-19 | Iniziato | Berenberg | Buy |
| 2019-12-19 | Reiterato | Chardan Capital Markets | Buy |
| 2019-11-20 | Iniziato | Oppenheimer | Outperform |
| 2019-11-13 | Iniziato | BofA/Merrill | Buy |
| 2019-05-23 | Ripresa | Goldman | Neutral |
| 2019-04-12 | Iniziato | Evercore ISI | Outperform |
| 2019-03-06 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2019-03-05 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2019-01-23 | Iniziato | UBS | Neutral |
| 2018-10-01 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-08-13 | Reiterato | Stifel | Buy |
| 2018-08-07 | Aggiornamento | Stifel | Hold → Buy |
| 2018-05-04 | Reiterato | Stifel | Hold |
| 2018-03-28 | Iniziato | Evercore ISI | In-line |
Mostra tutto
Alnylam Pharmaceuticals Inc Borsa (ALNY) Ultime notizie
Why (ALNY) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Morgan Stanley Maintains Alnylam Pharmaceuticals(ALNY.US) With Hold Rating, Maintains Target Price $370 - Moomoo
AI-Driven RNAi Push and Nordic Expansion Might Change The Case For Investing In Alnylam (ALNY) - simplywall.st
Alnylam Pharmaceuticals, Inc. (ALNY) and GENESIS Pharma Expand Commercial Partnership - Yahoo Finance
Alnylam Pharmaceuticals (ALNY), Inceptive Form $2B Partnership to Advance RNAi Drug Discovery - Yahoo Finance
Regeneron gets US, EU review for myasthenia gravis drug (REGN) - Seeking Alpha
Dyne Therapeutics adds ex-Sage CEO Barry Greene to board - Stock Titan
Alnylam (ALNY) Expands Its RNAi Therapeutics Reach Into Four More Nordic Countries - Insider Monkey
Alnylam Pharmaceuticals Inc (NASDAQ:ALNY) Passes the "Little Book" Test with Explosive Growth and Upward Momentum - ChartMill
Can Alnylam's Broader Portfolio Ease Its Dependence on Amvuttra? - Yahoo Finance
Barclays Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $527 - Moomoo
Alnylam Pharmaceuticals (ALNY) Investor Outlook: A Biotech Leader with 56.90% Upside Potential - DirectorsTalk Interviews
Alnylam Pharmaceuticals, Inc. (ALNY) Partners with Inceptive Nucleics to Accelerate Growth as A High-Growth Large-Cap Stock - Insider Monkey
ALNYLAM PHARMACEUTICALS INC (NASDAQ:ALNY): A Decent Value Play with Strong Growth at a Discount to Peers - ChartMill
Alnylam Pharmaceuticals unveils 2030 targets, betting on AMVUTTRA and pipeline readouts - MSN
Alnylam Pharmaceuticals Inc (ALNY) Institutional Confidence - TradingKey
Alnylam Pharmaceuticals Inc (ALNY) Valuation: PE, PB & Fair Value Analysis - TradingKey
Alnylam Pharmaceuticals Inc (ALNY) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Alnylam Pharmaceuticals Inc (ALNY) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Alnylam Pharmaceuticals Inc - TradingKey
Does Alnylam’s Generative AI Pact With Inceptive Nucleics Redraw The R&D Bull Case For ALNY? - simplywall.st
Analysts Offer Insights on Healthcare Companies: MBX Biosciences, Inc. (MBX) and Alnylam Pharma (ALNY) - The Globe and Mail
Alnylam expands Genesis Pharma collaboration in Europe - MSN
Alnylam Taps Generative AI And Nordic Expansion As Market Lags Targets - Yahoo Finance
Understanding Momentum Shifts in (ALNY) - Stock Traders Daily
Alnylam Pharmaceuticals stock hits 52-week low at $282.71 By Investing.com - Investing.com Nigeria
Alnylam Pharmaceuticals stock hits 52-week low at $282.71 - Investing.com
Alnylam to Host Tenth “RNAi Roundtable” Webcast Series - BioSpace
Can Alnylam Rely on Amvuttra to Sustain Its Rapid Sales Momentum? - The Globe and Mail
Andra AP fonden Grows Stock Holdings in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
ALNY News | ALNYLAM PHARMACEUTICALS INC (NASDAQ:ALNY) - ChartMill
What Does the Alnylam-Inceptive AI Deal Entail - Kavout
Motley Fool Asset Management LLC Purchases 3,480 Shares of Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
GENESIS Pharma Broadens Partnership with Alnylam Pharmaceuticals for RNAi Therapeutics Across Nordic Markets - World Business Outlook
A Look At Alnylam Pharmaceuticals (ALNY) Valuation As 2030 Goals And AI Partnership Refocus Growth Expectations - simplywall.st
Genesis and Alnylam Expand Partnership to Commercialize RNAi Therapeutics for Nordic Region - Contract Pharma
Alnylam Stock Is Running Its Own Race. Here’s What That Means for Your Portfolio. - Trefis
Alnylam expands Genesis Pharma deal in Europe (ALNY:NASDAQ) - Seeking Alpha
Genesis Pharma expands Alnylam partnership to Nordic markets - Investing.com
Genesis Pharma expands Alnylam partnership to Nordic markets By Investing.com - Investing.com South Africa
Junevity Partners with Sunrise BioVentures as Advisors to Accelerate siRNA Therapeutic Development - Business Wire
GENESIS Pharma Expands Strategic Commercial Partnership with Alnylam Pharmaceuticals for RNAi Therapeutics to the Nordic Region - Stock Titan
Alnylam Stock Is Running Its Own Race. Here's What That Means for Your Portfolio. - Trefis
Alnylam Pharmaceuticals Unveils 2030 Targets, Betting on AMVUTTRA and Pipeline Readouts - Yahoo Finance
Fiera Capital Corp Purchases 16,916 Shares of Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Alnylam to collaborate with Inceptive to use AI for RNAi therapy development - MSN
Alnylam Slides as Investors Refocus on Near-term Amvuttra Growth After Recent AI-deal Headlines - Moomoo
Bloom Energy, Astera Labs, Alnylam, Reddit could be among next adds to S&P 500 - MSN
Bloom Energy, Astera Labs, Alnylam, Reddit Could Be Among Next Adds to S&P 500 - Barron's
City banks nearly $100M for next-gen RNAi drugs - BioPharma Dive
Alnylam Pharmaceuticals (NASDAQ:ALNY) Shares Down 5%What's Next? - MarketBeat
Alnylam Pharmaceuticals Inc Azioni (ALNY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.15%
0.11%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):